SBI Biotech aims to develop new treatment methods and pharmaceuticals in two areas of specialization: autoimmune diseases and cancer. A core staff of research personnel who have led the world in the field of immune modulating factors and cytokine is driving acceleration of research and development that makes full use of the latest developments in molecular immunology and genetic engineering.

Furthermore, SBI Biotech has long placed importance on alliances with leading biotech venture companies around the world. For instance, the company is engaged in a development project in partnership with Changchun Huapu Biotechnology of China in the field of therapeutic nucleic acid drugs, which are next-generation biotech-based drugs. In addition, the company has expanded its R&D network in Asia, the U.S., and Europe and is pursuing clinical research in those countries.

In the fields of fundamental research for drug discovery and commercialization of drug products, SBI Biotech aims for dramatic growth as the world’s first joint drug discovery bio-venture firm backed by partners in Japan, the U.S., China, South Korea, and other countries.